Table 3 Parameters of simultaneous recordings of bladder pressure + urethral perfusion pressure (BP + UPP) in Sham and diabetic rats at 16 weeks after induction of DM (A), and before and after L-arginine-(B), or tadalafil-(C) in DM rats.

From: Pathophysiological changes of the lower urinary tract behind voiding dysfunction in streptozotocin-induced long-term diabetic rats

  

Baseline UPP (cmH2O)

UPP relaxation (cmH2O)

UPP nadir (cmH2O)

Urethral relaxation duration (s)

Average UPP during HFO (cmH2O)

HFO amplitude (cmH2O)

HFO duration (s)

HFO rate (Hz)

Intravesical pressure threshold for inducing urethral relaxation (cmH2O)

Max reflex bladder contraction amplitude (cmH2O)

A

Sham baseline (N = 6)

29.4 ± 3.75

26.0 ± 3.47

7.93 ± 1.19

28.5 ± 2.11

11.2 ± 1.06

3.24 ± 0.44

15.9 ± 2.39

3.17 ± 0.35

21.2 ± 2.02

60.7 ± 5.13

DM baseline (N = 6)

40.4 ± 4.20

30.2 ± 4.72

13.1 ± 1.14*

34.2 ± 3.35

20.2 ± 1.21**

2.72 ± 0.28

17.3 ± 2.54

2.86 ± 0.28

19.3 ± 3.00

69.9 ± 9.20

B

DM baseline (N = 6) (before i.v.-administration)

27.6 ± 3.95

20.8 ± 4.04

12.8 ± 1.65

21.9 ± 2.37

18.0 ± 1.67

2.01 ± 0.13

11.0 ± 1.18

3.43 ± 0.47

24.2 ± 5.10

55.2 ± 1.94

DM L-arginine (after i.v.-administration)

24.4 ± 2.95

18.8 ± 2.41

11.5 ± 1.70#

22.6 ± 1.94

16.2 ± 1.59#

1.92 ± 0.13

11.5 ± 1.08

3.50 ± 0.50

21.5 ± 3.55

50.9 ± 2.29

C

DM baseline (N = 6) (before i.v.-administration)

31.1 ± 4.76

25.9 ± 3.63

9.42 ± 1.45

31.6 ± 4.74

18.4 ± 3.77

2.60 ± 0.59

14.4 ± 2.12

3.01 ± 0.36

18.0 ± 1.58

58.7 ± 3.74

DM tadalafil (after i.v.-administration)

30.6 ± 4.69

24.6 ± 4.15

9.11 ± 1.11

31.2 ± 3.74

14.8 ± 2.76#

2.66 ± 0.74

13.8 ± 1.61

3.17 ± 0.36

16.5 ± 2.20

56.5 ± 2.70

  1. Values are expressed as the mean ± SEM.
  2. *P < 0.05, **P < 0.01: significant differences compared with Sham baseline (Mann-Whitney U-test).
  3. #P < 0.05, ##P < 0.01: significant differences compared with DM baseline (each before drug-administration, paired Student’s t-test).
Back to article page